

**In the Claims**

Please cancel claims 1- 49 prior to calculating fees.

Please re-write the claims as shown below.

1-49. (Cancelled)

50. (Original) A sustained release device comprising an agent that reduces platelet count in a subject, wherein the agent is released for at least 7 days.

51. (Original) The sustained release device of claim 50, further comprising an agent for treating vascular disease or complication.

52. (Original) The sustained release device of claim 50, wherein the agent for treating vascular disease or complication is selected from the group consisting of an anti-coagulant agent, a fibrinolytic agent and an inhibitor of platelet function

53. (Original) The sustained release device of claim 50, wherein the agent is released in an amount effective to reduce platelet count in a subject to below normal levels.

54. (Original) The sustained release device of claim 50, wherein the agent is anagrelide or a derivative of anagrelide.

55. (Original) The sustained release device of claim 50, wherein the agent is released at a rate ranging from 30 g/kg/day to 150 g/kg/day.

56. (Original) The sustained release device of claim 50, wherein the agent is released at a rate ranging from 1 g/kg/day to 150 g/kg/day.

57. (Original) The sustained release device of claim 50, wherein the agent is released for at least 30 days.

58. (Original) The sustained release device of claim 50, wherein the agent is released for at least 6 months.

59. (Original) The sustained release device of claim 50, wherein the agent is released for at least 1 year.

60. (Original) The sustained release device of claim 50, wherein the agent is released for at least 5 years.

61. (Original) The sustained release device of claim 50, wherein the agent is released in an effective amount that does not affect platelet function.